The ongoing dedicated ophthalmic trial named as FOCUS study, which aims to evaluate semaglutides long-term effects on diabetic retinopathy, is now ongoing and could contribute to a comprehensive understanding of the true risk-benefit profile of these agents in patients with or at risk for diabetic retinopathy (NCT03811561) [104]
They help convert fat into energy, boost vitality, and improve liver detoxification, making weight loss more sustainable
[5] Patients prescribed GLP-1 agonists often have type 2 diabetes or obesity, conditions independently associated with increased rates of osteoarthritis and other musculoskeletal disorders
This way, healthcare providers can give better, more tailored care
This dual benefit likely stems from the fact that both overeating and nicotine dependence activate overlapping reward and addiction circuits in the brain
Statistical analyses Data are presented as mean standard deviation (SD) and were confirmed to follow a normal distribution